Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined With Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)

NCT00869401 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT00869401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00869401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined With Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2009
Completion date
November 15, 2019
Enrollment
217 (actual)
Sites
207

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors